Abstract 1673P
Background
Imposter Syndrome (IS) is defined as “the inability to internalize achievement and a tendency to attribute success to external factors such as luck, error, or personal connections. It has been associated with psychological distress, emotional suffering, and significant mental health issues. It has also been associated with Burnout (BO), characterized by the emotional exhaustion of individuals in their careers, depersonalization toward other individuals, and a decrease in the sense of personal accomplishments. The study aimed to evaluate the factors associated with IS and its association with BO in medical oncologists (MOs).
Methods
A cross-sectional study was conducted focusing on the MOs actively working in the field. They were invited to the study via mailing list. The sociodemographic and academic data were collected. The IS scores (ISS) was tested using the Clance imposter phenomenon Scale and BO was tested by using the Maslach burnout inventory. The subscales of BO; emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA) were analyzed. The characteristics associated with IS and BO were tested by univariate and multivariate analysis.
Results
In the study, 417 MOs with a median age of 40(29-68) were evaluated. The mean of ISS was 50.8+/-15.3, and 122(29.3%) participants had high ISS. The multivariate analysis revealed that female gender was the only factor associated with high ISS (OR: 1.85, CI95%, 1.1- 2.9, p=0.009). While there was a strong positive correlation between ISS and EE (r=0.54, p<0.001) and DP (r=0.48, p<0.001), a strong and negative correlation was found between ISS and PA score (r= -0.41, p<0.001). In the multivariate analysis; high ISS score was the only statistically significant parameter associated with a high EE score (OR:5.03, CI 95% 3.1-8.0, p<0.001), high DP scores (OR=3.4, CI 95% 1.8- 6.5, p<0.001) and low PA scores. (OR=3.73, CI 95% 1.9- 7.1, p<0.001).
Conclusions
The results of the study indicated that IS is prevalent in MOs. The MOs with IS were more emotionally exhausted and more depersonalized. In addition, they had less feeling of personal accomplishment. The IS and its consequences on MOs should be further studied and the strategies to cope with IS should be developed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11